Adam Wilkinson

Adam Wilkinson is VP Pre-Clinical Development at Microbiotica. Adam is responsible for managing Pre-Clinical Development activities in the company including novel manufacturing and analytical technologies for Microbiotica’s pipeline of live bacterial products. He has more than 16 years of experience within the biotech and biopharmaceutical industry, including developing microbial engineering technologies, manufacturing process development and transfer, toxicology, project management, and regulatory submissions.

Adam was previously Head of R&D at Phico Therapeutics and oversaw all activities from Discovery through to Clinical Development, including all aspects of CMC, PK/PD, regulatory submissions, and established an extensive IP portfolio for novel live bacteriophage anti-bacterial products. He has latterly worked as a consultant supporting biotech start-ups and academic groups in establishing their pre-clinical development programs and in overseeing GMP manufacturing.

Adam holds a degree in Microbiology from the University of Reading and a Ph.D. in Bacterial Quorum Sensing from the John Innes Centre, Norwich UK. He undertook post-doctoral research at the MRC Laboratory of Molecular Biology in yeast mRNA splicing mechanisms, and at the University of East Anglia in DNA ligases.